Wan, Eric Yuk Fai;
Chui, Celine Sze Ling;
Ng, Vanessa Wai Sei;
Wang, Yuan;
Yan, Vincent Ka Chun;
Lam, Ivan Chun Hang;
Fan, Min;
... Wong, Ian Chi Kei; + view all
(2023)
Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell’s Palsy: A Nested Case-Control and Self-Controlled Case Series Study.
Clinical Infectious Diseases
, 76
(3)
e291-e298.
10.1093/cid/ciac460.
Preview |
Text
Wong_Bell's_Palsy_vaccine_follow-up_study_manuscript revision_CID_v2.1 clean.pdf Download (323kB) | Preview |
Abstract
BACKGROUND: Observable symptoms of Bell’s palsy following vaccinations may arouse concern over the safety profiles of novel COVID-19 vaccines in the general public. However, there are only a few studies on Bell’s palsy following mRNA COVID-19 vaccination with inconclusive findings. This study aimed to update the previous analysis on the risk of Bell’s palsy following mRNA (BNT162b2) COVID-19 vaccination. METHODS: This study included cases aged ≥16-years-old with a new diagnosis of Bell’s palsy within 28 days after BNT162b2 vaccinations from the population-based electronic health records in Hong Kong, using a nested case-control and self-controlled case series (SCCS) analyses were employed. The association between Bell’s palsy and BNT162b2 was evaluated using conditional logistic and Poisson regression in nested case-control and SCCS analysis, respectively. RESULTS: A total of 54 individuals were newly diagnosed with Bell’s palsy after BNT162b2 vaccinations. The incidence of Bell’s palsy was 1.58 (95% CI:1.19-2.07) per 100,000 doses administered. The nested case-control analysis showed significant association between BNT162b2 vaccinations and Bell’s palsy (Adjusted OR: 1.543, 95%CI:1.123 - 2.121), with up to 1.112 excess events per 100,000 people receiving two doses of BNT162b2. An increased risk of Bell’s palsy was observed during the first 14 days after the second dose of BNT162b2 in both nested case-control (Adjusted OR: 2.325, 95%CI:1.414 – 3.821) and SCCS analysis (Adjusted IRR=2.44, 95%CI:1.32-4.50). CONCLUSION: There is an overall increased risk of Bell’s palsy following BNT162b2 vaccination, particularly within the first 14 days after the second dose, but the absolute risk was very low.
| Type: | Article |
|---|---|
| Title: | Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination With BNT162b2 Increased Risk of Bell’s Palsy: A Nested Case-Control and Self-Controlled Case Series Study |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/cid/ciac460 |
| Publisher version: | https://doi.org/10.1093/cid/ciac460 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10149981 |
Archive Staff Only
 |
View Item |
